YOUR SEARCH FOR Text 11 RESULTS
1 of Total
0000879169-24-000149 | 10-Q | Incyte
… Relations IR@incyte.com … 0000879169-24-000149 | 10-Q | Incyte …
2 of Total
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults wi
Press Release View all news Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic
3 of Total
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates | Incyte
Press Release View all news Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates October 28, 2025 at 7:00 AM EDT PDF
4 of Total
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in
… ) 4 McMillan K. (2014) Hidradenitis suppurativa: number of …
5 of Total
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
Press Release View all news Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs October 29, 2024 at 7:
6 of Total
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… ttps://www.businesswire.com/news/home/20250429096014/en/ Media media@incyte.com Investors …
7 of Total
Medical Information Contact Info US & European Locations | Incyte.com
… 089 20301 0899* Ireland 1800456748 Italy 800148268 0236049221* Netherlands 08000226756 …
8 of Total
Stock information | Incyte
… 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 …
9 of Total
Press Releases | Incyte
… 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 …
10 of Total
Financials | Incyte
… 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 …